- Home
- FULC
as of 02-17-2026 3:46pm EST
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
| Founded: | 2015 | Country: | N/A |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 707.9M | IPO Year: | N/A |
| Target Price: | $16.38 | AVG Volume (30 days): | 592.5K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $2.31 - $15.74 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered FULC Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Fulcrum Therapeutics Inc. (FULC)
Director
Avg Cost/Share
$10.72
Shares
15,000
Total Value
$160,857.00
Owned After
454,864
SEC Form 4
Director
Avg Cost/Share
$11.87
Shares
15,000
Total Value
$178,089.00
Owned After
454,864
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$12.92
Shares
3,452
Total Value
$44,599.84
Owned After
10,252
SEC Form 4
10% Owner
Avg Cost/Share
$14.20
Shares
4,175,139
Total Value
$58,377,021.32
Owned After
8,852,079
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Gould Robert J | FULC | Director | Feb 2, 2026 | Sell | $10.72 | 15,000 | $160,857.00 | 454,864 | |
| Gould Robert J | FULC | Director | Jan 2, 2026 | Sell | $11.87 | 15,000 | $178,089.00 | 454,864 | |
| Oltmans Curtis Gale | FULC | Chief Legal Officer | Dec 15, 2025 | Sell | $12.92 | 3,452 | $44,599.84 | 10,252 | |
| RA CAPITAL MANAGEMENT, L.P. | FULC | 10% Owner | Dec 8, 2025 | Sell | $14.20 | 4,175,139 | $58,377,021.32 | 8,852,079 |
Compare FULC vs Leading Stocks
See how FULC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "FULC Fulcrum Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.